{"id":"https://openalex.org/W7097640555","doi":null,"title":"25Biomarkers in CanCer 2015:7(s2) Oncogene Overdose: Too Much of a Bad Thing for Oncogene-Addicted Cancer Cells Supplementary Issue: Signaling Pathways as Biomarkers","display_name":"25Biomarkers in CanCer 2015:7(s2) Oncogene Overdose: Too Much of a Bad Thing for Oncogene-Addicted Cancer Cells Supplementary Issue: Signaling Pathways as Biomarkers","publication_year":2016,"publication_date":"2016-08-21","ids":{"openalex":"https://openalex.org/W7097640555"},"language":"en","primary_location":{"id":"pmh:oai:CiteSeerX.psu:10.1.1.789.7308","doi":null,"is_oa":false,"landing_page_url":"http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.789.7308","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"ftp://ftp.ncbi.nlm.nih.gov/pub/pmc/46/d4/bic-suppl.2-2015-025.PMC4681422.pdf","raw_type":"text"},"volume":null,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"Amit Dipak Amin","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Amit Dipak Amin","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"Soumya S. Rajan","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Soumya S. Rajan","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062640366","display_name":"Matthew J. Groysman","orcid":"https://orcid.org/0000-0002-4837-8729","observed_orcids":["https://orcid.org/0000-0002-4837-8729"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Matthew J. Groysman","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025849300","display_name":"Praechompoo Pongtornpipat","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Praechompoo Pongtornpipat","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":null,"display_name":"Jonathan H. Schatz","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jonathan H. Schatz","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.53914574,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":true,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.7324000000953674,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.7324000000953674,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.13220000267028809,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11287","display_name":"Cancer Genomics and Diagnostics","score":0.057999998331069946,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/oncogene-addiction","display_name":"oncogene addiction","score":0.9010000228881836},{"id":"https://openalex.org/keywords/acquired-drug-resistance","display_name":"acquired drug resistance","score":0.7789999842643738},{"id":"https://openalex.org/keywords/targeted-therapy","display_name":"targeted therapy","score":0.6269999742507935},{"id":"https://openalex.org/keywords/braf-mutation","display_name":"BRAF mutation","score":0.5899999737739563},{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.9649999737739563},{"id":"https://openalex.org/keywords/anaplastic-large-cell-lymphoma","display_name":"anaplastic large cell lymphoma","score":0.9990000128746033},{"id":"https://openalex.org/keywords/intermittent-dosing","display_name":"intermittent dosing","score":0.9100000262260437},{"id":"https://openalex.org/keywords/acute-lymphoblastic-leukemia","display_name":"acute lymphoblastic leukemia","score":0.7960000038146973},{"id":"https://openalex.org/keywords/oncogenic-signaling","display_name":"oncogenic signaling","score":0.7279999852180481}],"concepts":[{"id":"https://openalex.org/C2781018059","wikidata":"https://www.wikidata.org/wiki/Q207609","display_name":"Oncogene","level":4,"score":0.6771000027656555},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6621999740600586},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.6297000050544739},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5983999967575073},{"id":"https://openalex.org/C62478195","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signal transduction","level":2,"score":0.5059999823570251},{"id":"https://openalex.org/C117643217","wikidata":"https://www.wikidata.org/wiki/Q17824987","display_name":"Anaplastic lymphoma kinase","level":4,"score":0.461899995803833},{"id":"https://openalex.org/C2779338263","wikidata":"https://www.wikidata.org/wiki/Q208414","display_name":"Lymphoma","level":2,"score":0.44449999928474426},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.4302000105381012},{"id":"https://openalex.org/C2994294914","wikidata":"https://www.wikidata.org/wiki/Q1645075","display_name":"Acquired resistance","level":3,"score":0.42640000581741333},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.4097000062465668},{"id":"https://openalex.org/C96232424","wikidata":"https://www.wikidata.org/wiki/Q4118072","display_name":"Cancer cell","level":3,"score":0.3547999858856201},{"id":"https://openalex.org/C1491633281","wikidata":"https://www.wikidata.org/wiki/Q7868","display_name":"Cell","level":2,"score":0.3012000024318695},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.27469998598098755},{"id":"https://openalex.org/C114851261","wikidata":"https://www.wikidata.org/wiki/Q12147416","display_name":"Drug resistance","level":2,"score":0.2687999904155731},{"id":"https://openalex.org/C555283112","wikidata":"https://www.wikidata.org/wiki/Q1637543","display_name":"Carcinogenesis","level":3,"score":0.26589998602867126},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.2605000138282776},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.25769999623298645},{"id":"https://openalex.org/C3018449070","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signalling pathways","level":3,"score":0.2524000108242035},{"id":"https://openalex.org/C51785407","wikidata":"https://www.wikidata.org/wiki/Q2627568","display_name":"Effector","level":2,"score":0.2515999972820282}],"mesh":[],"locations_count":1,"locations":[{"id":"pmh:oai:CiteSeerX.psu:10.1.1.789.7308","doi":null,"is_oa":false,"landing_page_url":"http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.789.7308","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"ftp://ftp.ncbi.nlm.nih.gov/pub/pmc/46/d4/bic-suppl.2-2015-025.PMC4681422.pdf","raw_type":"text"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9537000060081482,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2473598636","https://openalex.org/W2215206605","https://openalex.org/W2477592035","https://openalex.org/W2118099546","https://openalex.org/W3175894715","https://openalex.org/W4398234659","https://openalex.org/W2081783238","https://openalex.org/W2000821132","https://openalex.org/W1976577472","https://openalex.org/W4253811159"],"abstract_inverted_index":{"ABSTR":[0],"ACT:":[1],"Acquired":[2],"resistance":[3,24],"to":[4,36,63,126],"targeted":[5],"inhibitors":[6,20],"remains":[7,38],"a":[8,48],"major,":[9],"and":[10,26,108,136],"inevitable,":[11],"obstacle":[12],"in":[13,40,54,80,99,106,116,133],"the":[14,69,109],"treatment":[15],"of":[16,57,71,104,138],"oncogene-addicted":[17],"cancers.":[18],"Newer-generation":[19],"may":[21,51,61,123,145],"help":[22],"overcome":[23],"mutations,":[25],"inhibitor":[27],"combinations":[28],"can":[29],"target":[30],"parallel":[31],"pathways,":[32],"but":[33],"durable":[34],"benefit":[35],"patients":[37],"elusive":[39],"most":[41],"clinical":[42],"scenarios.":[43],"Now,":[44],"recent":[45,102],"studies":[46,103,137],"suggest":[47,142],"third":[49],"approach":[50],"be":[52,124,146],"available":[53],"some":[55,134],"cases\u2014exploitation":[56],"oncogene":[58,87],"over-expression":[59],"that":[60,143],"arise":[62],"promote":[64],"resistance.":[65],"Here,":[66],"we":[67],"discuss":[68],"importance":[70],"maintaining":[72],"oncogenic":[73],"signaling":[74],"at":[75],"\u201c":[76],"just-right":[77],"\u201d":[78],"levels":[79],"cells,":[81],"with":[82],"too":[83,94],"much":[84],"signaling,":[85],"or":[86],"overdose,":[88],"being":[89],"potentially":[90],"as":[91,93],"detrimental":[92],"little.":[95],"This":[96],"is":[97],"highlighted":[98],"particular":[100],"by":[101],"mutant-BRAF":[105],"melanoma":[107],"fusion":[110],"kinase":[111,114],"nucleophosmin\u2013anaplastic":[112],"lymphoma":[113],"(NPM\u2013ALK)":[115],"anaplastic":[117],"large":[118],"cell":[119],"lymphoma.":[120],"Oncogene":[121],"overdose":[122],"exploitable":[125],"prolong":[127],"tumor":[128],"control":[129],"through":[130],"intermittent":[131],"dosing":[132],"cases,":[135],"acute":[139],"lymphoid":[140],"leukemias":[141],"it":[144],"specifically":[147],"pharmacologically":[148],"inducible.":[149]},"counts_by_year":[],"updated_date":"2026-10-12T09:40:04.860316","created_date":"2025-10-27T00:00:00"}